Compare NIE & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIE | GOSS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.1M | 615.7M |
| IPO Year | N/A | 2018 |
| Metric | NIE | GOSS |
|---|---|---|
| Price | $25.56 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.90 |
| AVG Volume (30 Days) | 46.3K | ★ 21.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | ★ 78.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $114,701,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.54 | $0.33 |
| 52 Week High | $26.00 | $3.87 |
| Indicator | NIE | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 14.80 |
| Support Level | $24.71 | N/A |
| Resistance Level | $25.62 | $1.31 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 76.00 | 3.37 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.